Literature DB >> 3882284

Growth of transplantable melanoma and leukaemia and prevention of virus-induced leukaemia in long lived radiation chimeras constructed with unmanipulated bone marrow.

W Pierpaoli.   

Abstract

Haemopoietic radiation chimeras across the H-2 barrier (BALB/c----C57Bl/6; H-2d----H-2b chimeras and vice versa) have been studied for their capacity to suppress the growth, or to reject, transplantable B16 melanotic melanoma and radiation leukaemia virus-induced, transplantable leukaemia. Also, radiation leukaemia virus (RadLV) obtained from the thymus of leukaemic C57Bl/6 mice was injected i.p. into established chimeras (H-2d----H-2b). As expected, long lived, graft versus host disease free allogeneic chimeras constructed with intact bone marrow were unable to reject the tumours both when recipients were BALB/c----C57Bl/6 or C57Bl/6----BALB/c chimeras. However, also inoculation of a large number of immunocompetent cells from normal BALB/c mice into BALB/c----C57Bl/6 chimeras, failed to promote a rejection of the tumours. On the contrary, the same amount of syngeneic (BALB/c) immunocompetent cells prevented growth of melanoma when transferred into athymic nude BALB/c mice, while the tumour grew unimpaired in untreated athymic nude BALB/c mice. The same type of H-2d----H-2b chimeras displayed complete resistance to inculation of leukaemogenic H-2b restricted RadLV while all H-2b----H-2b, syngeneically reconstituted mice developed disseminated leukaemia. These findings demonstrate that: (a) a powerful suppressive principle operates in the chimeras which does not allow effector function and anti-tumour activity of passively transferred normal, mature T cells from resistant BALB/c mice. Thus, no H-2 restriction of donor T cells can be advocated for suppression of anti-tumour effector functions in the chimeras. (b) New donor (BALB/c, H-2d) marrow character in the H-2d----H-2b chimeras prevents expression of the H-2b restricted viral activity and leukaemogenic transformation and/or proliferation.

Entities:  

Mesh:

Year:  1985        PMID: 3882284      PMCID: PMC1577165     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Immunology of fully H-2 incompatible bone marrow chimeras induced in specific-pathogen-free mice: evidence for generation of donor- and host-H-2 restricted helper and cytotoxic T cells.

Authors:  S Aizawa; T Sado; M Muto; E Kubo
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

2.  Rejection of P2 skin grafts by long-lived H-2-incompatible graft-versus-host-disease-free bone marrow chimeras (P1 leads to P2).

Authors:  G J Maestroni; W Pierpaoli
Journal:  Transplantation       Date:  1983-10       Impact factor: 4.939

3.  H-2 restriction of adoptive immunotherapy of advanced tumors.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

4.  Leukemia relapse in donor cells after allogeneic bone-marrow transplantation.

Authors:  P E Newburger; S A Latt; J M Pesando; K Gustashaw; M Powers; R S Chaganti; R J O'Reilly
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

5.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.

Authors:  P L Weiden; K M Sullivan; N Flournoy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

6.  Enduring allogeneic marrow engraftment via nonspecific bone-marrow-derived regulating factors (MRF).

Authors:  W Pierpaoli; G J Maestroni; E Sache
Journal:  Cell Immunol       Date:  1981-01-01       Impact factor: 4.868

7.  Prevention of AKR leukemia by transplanting H-2-incompatible allogeneic bone marrow requires the maintenance of chimerism.

Authors:  E E Emeson; F M Weintraub
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

8.  Long-term survival of murine allogeneic bone marrow chimeras: effect of anti-lymphocyte serum and bone marrow dose.

Authors:  A J Norin; E E Emeson; F J Veith
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

9.  Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone.

Authors:  D A Vallera; C C Soderling; G J Carlson; J H Kersey
Journal:  Transplantation       Date:  1981-03       Impact factor: 4.939

10.  Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice.

Authors:  K Onoé; G Fernandes; R A Good
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Graft versus leukemia in bone marrow transplantation.

Authors:  M Boranić
Journal:  Blut       Date:  1988-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.